Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Musculin (MSC) is a basic helix-loop-helix transcriptional repressor capable of binding E-box elements as a homodimer or as a heterodimer with E2A proteins such as TCF3/E47[1][6]. It primarily functions to inhibit the transcriptional activity of E47, thereby acting as a negative regulator of antigen-dependent B-cell differentiation and is a downstream target of the B-cell receptor signal transduction pathway[1]. It also modulates human T-helper 17 cell responses to interleukin 2, influencing STAT5B activity in immune regulation[5]. Musculin is associated with diseases such as rhabdomyosarcoma and severe congenital neutropenia, X-linked[1]. Its paralog is TCF21, and it may play context-specific roles in cellular development and immune cell differentiation[2][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Musculin (MSC).